Pharmacotherapeutic advances for recurrent urinary tract infections in women

References

• Wagenlehner FM, Weidner W, Naber KG. An update on uncomplicated urinary tract infections in women. Curr Opin Urol. 2009 Jul;19(4):368–374.
   PubMed Web of Science ®Google Scholar
• Bonkat G, Bartoletti RR, Bruyère F, et al. Guidelines on urological infections. European Association of Urology;2019. http://uroweb.org/guideline/Urological Infections/.
   Google Scholar
• Alidjanov JF, Abdufattaev UA, Makhsudov SA, et al. The acute cystitis symptom score for patient-reported outcome assessment. Urol Int. 2016;97(4):402–409.
   PubMed Web of Science ®Google Scholar
• Clayson D, Wild D, Doll H, et al. Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI symptom assessment questionnaire. BJU Int. 2005 Aug;96(3):350–359.
   PubMed Web of Science ®Google Scholar
• Nicolle LE. AMMI canada guidelines committee*. Complicated urinary tract infection in adults. 2005;16(6):349–360. Can J Infect Dis Med Microbiol.
   PubMedGoogle Scholar
• Jhang JF, Kuo HC. Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention. Ci Ji Yi Xue Za Zhi. 2017;29(3):131–137.
   PubMedGoogle Scholar
• Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob Agents. 2001;17(4):259–268.
   PubMed Web of Science ®Google Scholar
• Wageniehner FME, Vahlensieck W, Bauer HW. et al. Prevention of recurrent urinary tract infections. Minerva Urol Nefrol. 2013;65(1):9–20.
   PubMed Web of Science ®Google Scholar
• Jung C, Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women. Climacteric. 2019;22(3):242–249.
   PubMed Web of Science ®Google Scholar
• Ha US, Cho YH. Immunostimulation with Escherichia coli extract: prevention of recurrent urinary tract infections. Int J Antimicrob Agents. 2008;31(Suppl 1):S63–7.
   PubMedGoogle Scholar
• Beerepoot M, Geerlings S. Non-antibiotic prophylaxis for urinary tract infections. Pathogens. 2016;5(2):36.
   Web of Science ®Google Scholar
• Bauer HW, Alloussi S, Egger G, et al. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47(4):542–548. discussion 548.
   PubMed Web of Science ®Google Scholar
• Prattley S, Geraghty R, Moore M, et al. Role of vaccines for recurrent urinary tract infections: a systematic review. Eur Urol Focus. 2019;6(3):593-604.
   PubMedGoogle Scholar
• Ahn ST, Kim SW, Kim JW, et al. Does urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli show same antibiotic resistance when it recurs? J Infect Chemother. 2019;25(7):498–502.
   PubMed Web of Science ®Google Scholar
• Meier S, Weber R, Zbinden R, et al. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39(4):333–340.
   PubMed Web of Science ®Google Scholar
• Spaulding CN, Klein RD, Schreiber HL 4th, et al. Precision antimicrobial therapeutics: the path of least resistance?. NPJ Biofilms Microbiomes 2018;4:4.
   PubMed Web of Science ®Google Scholar
• Sheu CC, Chang YT, Lin SY, et al. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80.
   PubMed Web of Science ®Google Scholar
• Crivelli JJ, Alhalabi F, Zimmern PE. Electrofulguration in the advanced management of antibiotic-refractory recurrent urinary tract infections in women. Int J Urol. 2019;26(6):662–668.
   PubMed Web of Science ®Google Scholar
• Bergamin PA, Kiosoglous AJ. Surgical management of recurrent urinary tract infections: a review. Transl Androl Urol. 2017;6(Suppl 2):S153–S162.
   PubMedGoogle Scholar
• McLellan LK, Hunstad DA. Urinary tract infection: pathogenesis and outlook. Trends Mol Med. 2016;22(11):946–957.
   PubMed Web of Science ®Google Scholar
• Flores-Mireles AL, Walker JN, Caparon M, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–284.
   PubMed Web of Science ®Google Scholar
• Lüthje P, Brauner A. Virulence factors of uropathogenic E. coli and their interaction with the host. Adv Microb Physiol. 2014;65:337–372.
   PubMed Web of Science ®Google Scholar
• Garofalo CK, Hooton TM, Martin SM, et al. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect Immun. 2007;75(1):52–60.
   PubMed Web of Science ®Google Scholar
• Anderson GG, Dodson KW, Hooton TM, et al. Intracellular bacterial communities of uropathogenic Escherichia coli in urinary tract pathogenesis. Trends Microbiol. 2004;12(9):424–430.
   PubMed Web of Science ®Google Scholar
• Glover M, Moreira CG, Sperandio V, et al. Recurrent urinary tract infections in healthy and nonpregnant women. Urol Sci. 2014;25(1):1–8.
   PubMedGoogle Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250–259.
   PubMed Web of Science ®Google Scholar
• Concia E, Bragantini D, Mazzaferri F. Clinical evaluation of guidelines and therapeutic approaches in multi drug-resistant urinary tract infections. J Chemother. 2017;29(sup1):19–28.
   PubMed Web of Science ®Google Scholar
• Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129(2):242–258.
   PubMed Web of Science ®Google Scholar
• McQuiston Haslund J, Rosborg Dinesen M, Sternhagen Nielsen AB, et al. Different recommendations for empiric first-choice antibiotic treatment of uncomplicated urinary tract infections in Europe. Scand J Prim Health Care. 2013;31(4):235–240.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79(3):271–289.
   PubMed Web of Science ®Google Scholar
• Tenney J, Hudson N, Alnifaidy H, et al. Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharm J. 2018;26(5):678–684.
   PubMed Web of Science ®Google Scholar
• Ikram R, Psutka R, Carter A, et al. An outbreak of multi-drug resistant Escherichia coli urinary tract infection in an elderly population: a case-control study of risk factors. BMC Infect Dis. 2015;15:224.
   PubMed Web of Science ®Google Scholar
• Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S–13S.
   PubMed Web of Science ®Google Scholar
• Ortega Martell JA, Naber KG, Milhem Haddad J, et al. Prevention of recurrent urinary tract infections: bridging the gap between clinical practice and guidelines in Latin America. Ther Adv Urol. 2019;11:1756287218824089. [published correction appears in Ther Adv Urol. 2019 Jul 05;11:1756287219863170]
   Web of Science ®Google Scholar
• Nickel JC. Practical management of recurrent urinary tract infections in premenopausal women. Rev Urol. 2005;7(1):11–17.
   PubMedGoogle Scholar
• Gopal M, Northington G, Arya L. Clinical symptoms predictive of recurrent urinary tract infections. Am J Obstet Gynecol. 2007;197(1):74.e1-4.
   PubMed Web of Science ®Google Scholar
• Kodner CM, Thomas Gupton EK. Recurrent urinary tract infections in women: diagnosis and management. Am Fam Physician. 2010;82(6):638–643.
   PubMed Web of Science ®Google Scholar
• Lichtenberger P, Hooton TM. Antimicrobial prophylaxis in women with recurrent urinary tract infections. Int J Antimicrob Agents. 2011 Dec;38:Suppl:36–41.
   PubMed Web of Science ®Google Scholar
• Albert X, Huertas I, Pereiró II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209
   PubMed Web of Science ®Google Scholar
• Jancel T, Dudas V. Management of uncomplicated urinary tract infections. West J Med. 2002;176(1):51–55.
   PubMedGoogle Scholar
• Bell BG, Schellevis F, Stobberingh E, et al. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014 Jan;9(14):13.
   Google Scholar
• Morton SC, Shekelle PG, Adams JL, et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. ArchPhys Med Rehabil. 2002;83:129–137.
   PubMed Web of Science ®Google Scholar
• Muller AE, Verhaegh EM, Harbarth S. Nitrofurantoin’s efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials. Clin Microbiol Infect. 2017;23(6):355–362.
   PubMed Web of Science ®Google Scholar
• Price JR, Guran LA, Gregory WT, et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016;215(5):548–560.
   PubMed Web of Science ®Google Scholar
• Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung. 2005;55(7):420–427.
   PubMed Web of Science ®Google Scholar
• Costantini E, Zucchi A, Salvini E, et al. Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial. Int Urogynecol J. 2014;25(9):1173–1178.
   PubMed Web of Science ®Google Scholar
• Cetti RJ, Venn S, Woodhouse CR. The risks of long-term nitrofurantoin prophylaxis in patients with recurrent urinary tract infection: a recent medico-legal case. BJU Int. 2009;103(5):567–569.
   PubMed Web of Science ®Google Scholar
• Madani Y, Mann B. Nitrofurantoin-induced lung disease and prophylaxis of urinary tract infections. Prim Care Respir J. 2012;21(3):337–341.
   PubMedGoogle Scholar
• Bergamin PA, Kiosoglous AJ. Non-surgical management of recurrent urinary tract infections in women. Transl Androl Urol. 2017;6(Suppl 2):S142–S152.
   PubMedGoogle Scholar
• Chernyak S, Salamon C. Intravesical antibiotic administration in the treatment of recurrent urinary tract infections: promising results from a case series. Female Pelvic Med Reconstr Surg. 2020;26:152–154.
   PubMed Web of Science ®Google Scholar
• Pietropaolo A, Jones P, Moors M, et al. Use and effectiveness of antimicrobial intravesical treatment for prophylaxis and treatment of recurrent urinary tract infections (UTIs): a systematic review. Curr Urol Rep. 2018;19(10):78.
   PubMed Web of Science ®Google Scholar
• Stalenhoef JE, van Nieuwkoop C, Menken PH, et al. Intravesical gentamicin treatment for recurrent urinary tract infections caused by multidrug resistant bacteria. J Urol. 2019;201(3):549–555.
   PubMed Web of Science ®Google Scholar
• van Nieuwkoop C, den Exter PL, Elzevier HW, et al. Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation. Int J Antimicrob Agents. 2010;36(6):485–490.
   PubMed Web of Science ®Google Scholar
• Stamatiou C, Petrakos G, Bovis C, et al. Efficacy of prophylaxis in women with sex induced cystitis. Clin Exp Obstet Gynecol. 2005;32(3):193–195.
   PubMedGoogle Scholar
• Melekos MD, Asbach HW, Gerharz E, et al. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol. 1997;157(3):935–939.
   PubMed Web of Science ®Google Scholar
• Moore EE, Hawes SE, Scholes D, et al. Sexual intercourse and risk of symptomatic urinary tract infection in post-menopausal women. J Gen Intern Med. 2008;23(5):595–599.
   PubMed Web of Science ®Google Scholar
• Stapleton A, Latham RH, Johnson C, et al. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial. JAMA. 1990;264(6):703–706.
   PubMed Web of Science ®Google Scholar
• Schaeffer AJ, Stuppy BA. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol. 1999;161(1):207–211.
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton TM, Roberts PL, et al. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med. 2001;135(1):9–16.
   PubMed Web of Science ®Google Scholar
• Epp A, Larochelle A. Urogynaecology committee, family physicians advisory committee. Recurrent urinary tract infection. J Obstet Gynaecol Can. 2010;32(11):1082–1090.
   PubMedGoogle Scholar
• Salomon J, Denys P, Merle C, et al. Prevention of urinary tract infection in spinal cord injured patients: safety and efficacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2 year follow-up. An observational prospective study. J Antimicrob Chemother. 2006 Apr;57(4):784–788.
   PubMed Web of Science ®Google Scholar
• Dinh A, Hallouin-Bernard MC, Davido B, et al. Weekly sequential antibioprophylaxis for recurrent UTI among patients with neurogenic bladder: a randomized controlled trial. Clin Infect Dis. 2019 Dec 23;ciz1207.
   PubMed Web of Science ®Google Scholar
• Perrotta C, Aznar M, Mejia R, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Pastijn A, Gevers R, et al. Estrogen therapy in older patients with recurrent urinary tract infections: a review. Int J Fertil Womens Med. 2004;49(2):71–74.
   PubMedGoogle Scholar
• Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180(5):1072–1079.
   PubMed Web of Science ®Google Scholar
• Ferrante KL, Wasenda EJ, Jung CE. Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial. Female Pelvic Med Reconstr Surg. 2019 Jun 19.
   PubMed Web of Science ®Google Scholar
• Simon JA, Altomare C, Cort S, et al. Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials. J Womens Health (Larchmt). 2018;27(1):14–23.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Di Pinto A, Sciuga V, et al. Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene. Gynecol Endocrinol. 2018;34(2):140–143.
   PubMed Web of Science ®Google Scholar
• Luczak T, Swanoski M. A review of cranberry use for preventing urinary tract infections in older adults. Consult Pharm. 2018;33(8):450–453.
   PubMed Web of Science ®Google Scholar
• Kontiokari T, Sundqvist K, Nuutinen M, et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001 Jun;322(7302):1571.
   PubMedGoogle Scholar
• Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD001321.
   PubMed Web of Science ®Google Scholar
• Maki KC, Kaspar KL, Khoo C, et al. Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection episodes in women with a recent history of urinary tract infection. Am J Clin Nutr. 2016;103(6):1434–1442.
   PubMed Web of Science ®Google Scholar
• Vostalova J, Vidlar A, Simanek V, et al. Are high proanthocyanidins key to cranberry efficacy in the prevention of recurrent urinary tract infection? Phytother Res. 2015;29(10):1559–1567.
   PubMed Web of Science ®Google Scholar
• Asma B, Vicky L, Stephanie D, et al. Standardised high dose versus low dose cranberry Proanthocyanidin extracts for the prevention of recurrent urinary tract infection in healthy women [PACCANN]: a double blind randomised controlled trial protocol. BMC Urol. 2018;18(1):29.
   PubMedGoogle Scholar
• Liska DJ, Kern HJ, Maki KC. Cranberries and urinary tract infections: how can the same evidence lead to conflicting advice? Adv Nutr. 2016 May;7(3):498–506.
   PubMed Web of Science ®Google Scholar
• O’Brien VP, Hannan TJ, Nielsen HV, et al. Drug and vaccine development for the treatment and prevention of urinary tract infections. Microbiol Spectr. 2016;4(1). 10.1128/microbiolspec.UTI-0013-2012.
   PubMed Web of Science ®Google Scholar
• Bauer HW, Rahlfs VW, Lauener PA, et al. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents. 2002;19(6):451–456.
   PubMed Web of Science ®Google Scholar
• Naber KG, Cho YH, Matsumoto T, et al. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009;33(2):111–119.
   PubMed Web of Science ®Google Scholar
• Kim KS, Kim JY, Jeong IG, et al. A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis. J Korean Med Sci. 2010;25(3):435–439.
   PubMed Web of Science ®Google Scholar
• Uehling DT, Hopkins WJ, Elkahwaji JE, et al. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol. 2003;170(3):867–869.
   PubMed Web of Science ®Google Scholar
• Hopkins WJ, Elkahwaji J, Beierle LM, et al. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007;177(4):1349-1353.
   Google Scholar
• Huttner A, Gambillara V. The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli. Clin Microbiol Infect. 2018;24(10):1046–1050.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Gómez MF, Padilla-Fernández B, García-Criado FJ, et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J. 2013;24(1):127–134.
   PubMed Web of Science ®Google Scholar
• Yang B, Foley S. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune®. BJU Int. 2018;121(2):289–292.
   PubMed Web of Science ®Google Scholar
• Ramírez Sevilla C, Gómez Lanza E, Manzanera JL, et al. Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects. BMC Infect Dis. 2019;19(1):901.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Betsi GI, Tokas T, et al. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs. 2006;66(9):1253–1261.
   PubMed Web of Science ®Google Scholar
• Beerepoot MA, Rietter G, Nys S, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012;172(9):704–712.
   PubMedGoogle Scholar
• Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: how promising is the use of probiotics? Indian J Med Microbiol. 2017;35(3):347–354.
   PubMed Web of Science ®Google Scholar
• Grin PM, Kowalewska PM, Alhazzan W, et al. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol. 2013;20(1):6607–6614.
   PubMed Web of Science ®Google Scholar
• Abad CL, Safdar N. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review. J Chemother. 2009;21(3):243–252.
   PubMed Web of Science ®Google Scholar
• Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52(10):1212–1217.
   PubMed Web of Science ®Google Scholar
• Wellens A, Garofalo C, Nguyen H, et al. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS One. 2008 Apr 30;3(4):e2040.
   PubMed Web of Science ®Google Scholar
• Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79–84.
   PubMed Web of Science ®Google Scholar
• Salinas-Casado J, Méndez-Rubio S, Esteban-Fuertes M, et al. Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections. Arch Esp Urol. 2018;71(2):169–177.
   PubMed Web of Science ®Google Scholar
• Domenici L, Monti M, Bracchi C, et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci. 2016;20(13):2920–2925.
   PubMed Web of Science ®Google Scholar
• Porru D, Parmigiani A, Tinelli C, et al. Oral D-mannose in recurrent urinary tract infections in women: A pilot study. World J Urol. 2014;7(3):208–213.
   Google Scholar
• Carlsson S, Wiklund NP, Engstrand L, et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide. 2001;5(6):580–586.
   PubMed Web of Science ®Google Scholar
• Ochoa-Brust GJ, Fernández AR, Villanueva-Ruiz GJ, et al. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Scand. 2007;86(7):783–787.
   PubMed Web of Science ®Google Scholar
• Wu S, Sun J. Vitamin D, receptor, and macroautophagy in inflammation and infection. Discov Med. 2011;11(59):325–335.
   PubMed Web of Science ®Google Scholar
• Jorde R, Sollid ST, Svartberg J, et al. Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years. Results from an RCT including 511 subjects. Infect Dis (Lond). 2016;48(11–12):823–828. .
   PubMed Web of Science ®Google Scholar
• Chwa A, Kavanagh K, Linnebur SA, et al. Evaluation of methenamine for urinary tract infection prevention in older adults: a review of the evidence. Ther Adv Drug Saf. 2019;10:2042098619876749.
   Web of Science ®Google Scholar
• MS S, SA L, SM P, et al. Effectiveness of methenamine for UTI prevention in older adults. Ann Pharmacother. 2020;54(4):359–363.
   PubMed Web of Science ®Google Scholar
• Hollyer I, Varias F, Ho B, et al. Safety and efficacy of methenamine hippurate for the prevention of recurrent urinary tract infections in adult renal transplant recipients: A single center, retrospective study. Transpl Infect Dis. 2019;21(3):e13063.
   PubMed Web of Science ®Google Scholar
• Pannek J. Prevention of recurrent urinary tract infections in neurourology. Eur Urol Focus. 2020 Feb 12:S2405-4569(20)30034–1.
   PubMedGoogle Scholar
• Leitner L, Sybesma W, Chanishvili N, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol. 2017;17:90.
   PubMed Web of Science ®Google Scholar
• Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012;66(9):891–896.
   PubMed Web of Science ®Google Scholar
• Anesi JA, Lautenbach E, Nachamkin I, et al. The role of extended-spectrum cephalosporin-resistance in recurrent community-onset Enterobacteriaceae urinary tract infections: a retrospective cohort study. BMC Infect Dis. 2019;19(1):163.
   PubMedGoogle Scholar
• Pitout JD. Enterobacteriaceae that produce extended-spectrum β-lactamases and AmpC β-lactamases in the community: the tip of the iceberg? Curr Pharm Des. 2013;19(2):257–263.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Rodriguez-Bano J. The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections. Clin Infect Dis. 2017;64(7):972–980.
   PubMed Web of Science ®Google Scholar
• Kim SA, Altshuler J, Paris D, et al. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae. Int J Antimicrob Agents. 2018;51(1):155–158.
   PubMed Web of Science ®Google Scholar
• Tullos JB, Stoudenmire LL, Pouliot JD. Piperacillin-tazobactam versus carbapenems for the treatment of nonbacteremic urinary tract infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae. Hosp Pharm. 2020;55(1):44–49.
   PubMed Web of Science ®Google Scholar
• Escolà-Vergé L, Pigrau C, Almirante B. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy. Infect Drug Resist. 2019;12:1853–1867.
   PubMed Web of Science ®Google Scholar
• Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination. Pharmacotherapy. 2015;35(7):701–715.
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Rybak JM, Rybak MJ. The β-lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015;35(8):755–770.
   PubMed Web of Science ®Google Scholar
• Mosley JF 2nd, Smith LL, Parke CK, et al. Ceftazidime-avibactam (Avycaz): for the treatment of complicated intra-abdominal and urinary tract infections. P T. 2016;41(8):479–483.
   Google Scholar
• Karlowsky JA, Biedenbach DJ, Kazmierczak KM, et al. Activity of ceftazidime-avibactam against extended-spectrum- and AmpC β-lactamase-producing enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014. Antimicrob Agents Chemother. 2016;60(5):2849–2857.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347.
   PubMed Web of Science ®Google Scholar
• Pullukcu H, Tasbakan M, Sipahi OR, et al. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents. 2007;29(1):62–65.
   PubMed Web of Science ®Google Scholar
• Senol S, Tasbakan M, Pullukcu H, et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother. 2010;22(5):355–357.
   PubMed Web of Science ®Google Scholar
• Qiao LD, Zheng B, Chen S, et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open. 2013;3(12):e004157.
   PubMed Web of Science ®Google Scholar
• Komp Lindgren P, Klockars O, Malmberg C, et al. Pharmacodynamic studies of nitrofurantoin against common uropathogens. J Antimicrob Chemother. 2015;70(4):1076–1082.
   PubMed Web of Science ®Google Scholar
• Tasbakan MI, Pullukcu H, Sipahi OR, et al. Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents. 2012;40(6):554–556.
   PubMed Web of Science ®Google Scholar
• Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect. 2008;14(Suppl 1):198–202.
   PubMed Web of Science ®Google Scholar
• Dewar S, Reed LC, Koerner RJ. Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother. 2014;69(2):303–308.
   PubMed Web of Science ®Google Scholar
• Graninger W. Pivmecillinam--therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003;22(Suppl 2):73–78.
   PubMed Web of Science ®Google Scholar
• Jansåker F, Frimodt-Møller N, Bjerrum L, et al. The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol. BMC Infect Dis. 2016;16(1):727.
   PubMedGoogle Scholar
• Raja NS. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae. Int J Clin Pract. 2019;73(9):1–5.
   PubMed Web of Science ®Google Scholar
• Bollestad M, Grude N, Solhaug S, et al. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. J Antimicrob Chemother. 2018;73(9):2503–2509.
   PubMed Web of Science ®Google Scholar
• Suay-García B, Pérez-Gracia MT. Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics (Basel). 2019;8(3):122.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Potoski BA, Buehrle D, et al. Estimating the treatment of carbapenem-resistant enterobacteriaceae infections in the United States using antibiotic prescription data. Open Forum Infect Dis. 2019;6(8):ofz344.
   PubMed Web of Science ®Google Scholar
• TB T, Velkov T, RL N, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016;48(6):592–597.
   PubMed Web of Science ®Google Scholar
• Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30(12):1279–1291.
   PubMed Web of Science ®Google Scholar
• Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(11):e3126.
   PubMed Web of Science ®Google Scholar
• Wu G, Abraham T, Saad N. Role of tigecycline for the treatment of urinary tract infections. J Pharm Technol. 2014;30(3):87–92.
   PubMedGoogle Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63(6):754–762.
   PubMed Web of Science ®Google Scholar
• Albin OR, Patel TS, Kaye KS. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections. Expert Rev Anti Infect Ther. 2018;16(12):865–876.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788–799.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018 Dec;7(4):439–455.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim J, Trinh S. Meropenem-vaborbactam (Vabomere™): another option for carbapenem-resistant enterobacteriaceae. P T. 2019;44(3):110–113.
   PubMedGoogle Scholar
• Eljaaly K, Alharbi A, Alshehri S, et al. Plazomicin: a novel aminoglycoside for the treatment of resistant gram-negative bacterial infections. Drugs. 2019;79(3):243–269.
   PubMed Web of Science ®Google Scholar
• Shaeer KM, Zmarlicka MT, Chahine EB, et al. Plazomicin: a next-generation aminoglycoside. Pharmacotherapy. 2019;39(1):77–93.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380(8):729–740.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, Kazmierczak KM, et al. In vitro activity of imipenem-relebactam against clinical isolates of gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program. Antimicrob Agents Chemother. 2018;62(7):e00169–18.
   PubMed Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020 ;70(9):1799-1808.
   PubMed Web of Science ®Google Scholar
• Brown ML, Motsch J, Kaye KS, et al. Evaluation of renal safety between imipenem/relebactam and colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections in the randomized, phase 3 RESTORE-IMI 1 study. Open Forum Infect Dis. 2020;7(3):ofaa054.
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris AG. Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections. Expert Opin Investig Drugs. 2014;23(6):751–757.
   PubMed Web of Science ®Google Scholar
• Engeler D, Baranowski AP, Borovicka J, et al. EAU guidelines on chronic pelvic pain. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen; 2018.
   Google Scholar
• Theoharides C. Treatment approaches for painful bladder syndrome/ interstitial cystitis. Drugs. 2007;67:215–235.
   PubMed Web of Science ®Google Scholar
• Hanno PM, Erickson D, Moldwin R, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545–1553.
   PubMed Web of Science ®Google Scholar
• Dellis AE, Kostakopoulos N, Papatsoris AG. Is there an effective therapy of interstitial cystitis/bladder pain syndrome? Expert Opin Pharmacother. 2019 Aug;20(12):1417–1419.
   PubMed Web of Science ®Google Scholar
• Dellis AE, Mozaffari S, Nikfar S, et al. Is there an appropriate strategy for treating co-morbid irritable bowel syndrome and bladder pain syndrome? Expert Opin Pharmacother. 2019 Mar;20(4):411–414.
   PubMed Web of Science ®Google Scholar
• Dellis AE, Papatsoris AG. Bridging pharmacotherapy and minimally invasive surgery in interstitial cystitis/bladder pain syndrome treatment. Expert Opin Pharmacother. 2018 Aug;19(12):1369–1373.
   PubMed Web of Science ®Google Scholar
• Borchert DH, Sheridan E, Papatsoris A, et al. The case for probiotics in urology. BJU Int. 2008 Feb;101(4):413–414.
   PubMed Web of Science ®Google Scholar
• Borchert D, Sheridan L, Papatsoris A, et al. Prevention and treatment of urinary tract infection with probiotics: review and research perspective. Indian J Urol. 2008 Apr;24(2):139–144.
   PubMedGoogle Scholar
• Abbo LM, Hooton TM. Antimicrobial stewardship and urinary tract infections. Antibiotics (Basel). 2014;3(2):174–192.
   PubMedGoogle Scholar
• Durkin MJ, Keller M, Butler AM, et al. An assessment of inappropriate antibiotic use and guideline adherence for uncomplicated urinary tract infections. Open Forum Infect Dis. 2018;5(9):ofy198.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Shapiro DJ, Hersh AL, et al. Outpatient antibiotic prescribing practices for uncomplicated urinary tract infection in women in the United States, 2002-2011. Open Forum Infect Dis. 2016;3(3):ofw159. eCollection 2016 Sep.
   PubMed Web of Science ®Google Scholar